• Ulcerative Colitis GSK2831781 Study Discontinued americanpharmaceuticalreview
    January 28, 2021
    Immutep Limited is advising its licensing partners, GSK, has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative ...
PharmaSources Customer Service